Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Blockbusters fend off generics

Posted 7 December 2021 AM

Pressure is mounting from generics manufacturers seeking to launch competitors to blockbuster brands as early as possible, and have patents declared invalid.

In response, pharmas are suing generics companies for threatening to infringe patents, and relying on patents for manufacturing and administration processes to delay the 'first generic' approved by the Therapeutic Goods Administration, which would trigger a price reduction under the Pharmaceutical Benefits Scheme.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.